|1.||Robertson, John F R: 19 articles (01/2016 - 02/2002)|
|2.||Howell, Anthony: 13 articles (09/2015 - 04/2002)|
|3.||Robertson, J F R: 11 articles (06/2010 - 08/2002)|
|4.||Nicholson, Robert I: 10 articles (01/2016 - 07/2002)|
|5.||Lykkesfeldt, Anne E: 9 articles (04/2015 - 03/2009)|
|6.||Clarke, Robert: 9 articles (06/2014 - 01/2005)|
|7.||Jordan, V Craig: 9 articles (11/2007 - 11/2003)|
|8.||Osborne, C Kent: 8 articles (07/2014 - 07/2003)|
|9.||Nephew, Kenneth P: 8 articles (01/2012 - 03/2003)|
|10.||Mauriac, Louis: 7 articles (08/2015 - 07/2003)|
|1.||Breast Neoplasms (Breast Cancer)
08/01/2011 - "Overall, these data indicate an improved benefit-risk profile for fulvestrant 500 mg versus 250 mg following failure on prior endocrine therapy, and suggest that fulvestrant 500 mg may be considered in future as initial endocrine treatment for advanced breast cancer."
05/01/2008 - "We conclude that, because of its therapeutic efficacy and its seemingly minimal effect on bone integrity, fulvestrant represents a new option for the hormonal treatment of breast cancer that deserves further clinical evaluation."
08/15/2002 - "These data confirm that fulvestrant is an additional, effective, and well-tolerated treatment for advanced breast cancer in postmenopausal women whose disease progressed on prior endocrine therapy."
02/01/2006 - "Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents."
09/01/2004 - "Therefore, fulvestrant is a versatile new treatment option for postmenopausal women with advanced breast cancer who have progressed on prior endocrine therapy."
01/15/1994 - "Treatment with ICI 182780 also resulted in a significant reduction in pS2 expression (P < 0.05) but this appeared unrelated to tumor ER status. "
01/01/2014 - "A single-agent AKT inhibitor combined with fulvestrant conferred superior efficacy in overcoming resistance, inducing apoptosis and tumor regression. "
05/01/2014 - "These results showed that combination of fulvestrant and chemotherapeutic agents might provide an effective treatment for ER- MDR breast cancers. "
10/01/2015 - "The clinical efficacy of fulvestrant, a selective ER degrader (SERD) that triggers receptor degradation, has confirmed that ESR1 often remains engaged in endocrine therapy resistant cancers. "
03/01/2006 - "Fulvestrant is a well-tolerated treatment and has efficacy against breast cancers that have progressed after therapy with a third-generation AI."
|3.||Neoplasm Metastasis (Metastasis)
01/01/2015 - "79.0 % of patients at fulvestrant administration had visceral metastases. "
12/01/2015 - "Fulvestrant is effective for ABC patients and may show greater efficacy in patients with few prior chemotherapy regimens, de novo metastatic disease and absence of liver metastasis. "
07/01/2015 - "The present findings suggest that, among Japanese patients with advanced, recurrent, ER-positive postmenopausal breast cancer, 500 mg fulvestrant is effective and safe in those without metastasis and a minimal history of receipt of previous treatment regimens."
07/01/2013 - "We analyzed the impact of Faslodex on tumor size, the extracellular matrix organization, the expression of matrix metalloproteinase (MMP)-2, and lung metastasis. "
12/01/2006 - "25 months after commencing fulvestrant treatment, the tumor had decreased in size to 4.8 x 3.5 x 3.2 cm, and the hepatic metastases were no longer detectable. "
09/01/1999 - "Faslodex may prove useful in the treatment of patients with diseases causing rapid skeletal maturation, such as precocious puberty."
01/01/2012 - "Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome."
01/01/2012 - "The objective of this study was to evaluate the safety and efficacy of fulvestrant (FaslodexTM), a pure estrogen receptor antagonist, in girls with progressive precocious puberty (PP) associated with McCune-Albright Syndrome (MAS). "
07/16/2015 - "The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib-fulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo-fulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001). "
11/01/2014 - "Fulvestrant was administered but disease progression was observed after 3 months. "
09/01/2012 - "twice daily on day 1 and day 4 weekly) after disease progression, continuing fulvestrant at the same dose. "
02/12/2011 - "Consequently, a regimen of fulvestrant 500 mg monthly with a loading dose was significantly more effective than a regimen of 250 mg monthly in postmenopausal women with disease progression. "
05/01/2009 - "Treatment consisted of single agent fulvestrant, 500 mg IM on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression. "
|6.||Estrogen Receptor Modulators (Antiestrogen)
|10.||N- (4- bromo- 2- fluorophenyl)- 6- methoxy- 7- ((1- methylpiperidin- 4- yl)methoxy)quinazolin- 4- amine (ZD6474)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|5.||Segmental Mastectomy (Lumpectomy)